Malignant mesothelioma without asbestos exposure diagnosed during EGFR-TKI treatment of lung adenocarcinoma: A case report

Xiaomin Niu; Chenglei Zhou; Aiyan Hu; Lingzi Su; Dan Lin; Hui Han; Yan Lu

doi:10.1016/j.ctarc.2021.100345

Malignant mesothelioma without asbestos exposure diagnosed during EGFR-TKI treatment of lung adenocarcinoma: A case report

Cancer Treat Res Commun. 2021:27:100345. doi: 10.1016/j.ctarc.2021.100345. Epub 2021 Feb 24.

Authors

Xiaomin Niu¹, Chenglei Zhou², Aiyan Hu³, Lingzi Su⁴, Dan Lin⁴, Hui Han⁴, Yan Lu⁵

Affiliations

¹ Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huaihai West Road, Shanghai, 200030, PR China.
² Foreign Language Teaching Center, Shanghai university of traditional Chinese medicine, 1200 Cailun Road, Shanghai, 201203, PR China.
³ Department of Pathology, Yueyang Hospital of integrated traditional Chinese and western medicine, Shanghai university of traditional Chinese medicine, 110 Ganhe Road, Shanghai, 200437, PR China.
⁴ Department of Cancer Center, Yueyang Hospital of integrated traditional Chinese and western medicine, Shanghai university of traditional Chinese medicine, 110 Ganhe Road, Shanghai, 200437, PR China.
⁵ Department of Cancer Center, Yueyang Hospital of integrated traditional Chinese and western medicine, Shanghai university of traditional Chinese medicine, 110 Ganhe Road, Shanghai, 200437, PR China. Electronic address: luyan7@163.com.

PMID: 33640705
DOI: 10.1016/j.ctarc.2021.100345

Abstract

Synchronous malignant mesothelioma (MM) and lung carcinoma are extremely rare in patients without a history of asbestos exposure and poses tremendous difficulties in clinical management. We report a patient without asbestos exposure diagnosed with MM during EGFR-TKI treatment of lung adenocarcinoma (LUAD), who responded to first-line chemotherapy with pemetrexed plus carboplatin and failed to subsequent systemic therapy. Clinicians should be careful about the possibility of MM comorbidity in LUAD patients whose lesions respond differently to EGFR-TKI, even in those without a history of asbestos exposure.

Keywords: EGFR-TKI resistance; Lung adenocarcinoma; Lung carcinoma; Malignant mesothelioma (mm).

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma of Lung / diagnosis
Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Drug Resistance, Neoplasm
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
Fatal Outcome
Humans
Lung Neoplasms / diagnosis
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Male
Mesothelioma, Malignant / diagnosis*
Mesothelioma, Malignant / drug therapy
Mesothelioma, Malignant / genetics
Mesothelioma, Malignant / secondary
Middle Aged
Neoplasms, Multiple Primary / diagnosis*
Neoplasms, Multiple Primary / drug therapy
Neoplasms, Multiple Primary / genetics
Neoplasms, Multiple Primary / pathology
Pleural Neoplasms / diagnosis*
Pleural Neoplasms / drug therapy
Pleural Neoplasms / genetics
Pleural Neoplasms / pathology
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use

Substances

Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors